Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung CancerLuis Paz‐Ares, Dariusz M. Kowalski, Alexander Luft et al.|New England Journal of Medicine|2018Cited by 3.7k
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trialMatthew D. Galsky, Enrique Grande, Stefano Panni et al.|The Lancet|2020Cited by 786
Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 StudySilvia Novello, Luis Paz‐Ares, Dariusz M. Kowalski et al.|Journal of Clinical Oncology|2023Cited by 541
Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).Luis Paz‐Ares, Dariusz M. Kowalski, Alexander Luft et al.|Journal of Clinical Oncology|2018Cited by 121
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 StudyAkihito Kawazoe, Reinhard Depenbusch, Rui‐Hua Xu et al.|Journal of Clinical Oncology|2024Cited by 77